Cargando…

Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study

BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jung Wha, Choi, Hwa Young, Ki, Moran, Jang, Eun Sun, Jeong, Sook-Hyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960981/
https://www.ncbi.nlm.nih.gov/pubmed/32616682
http://dx.doi.org/10.5009/gnl19387
_version_ 1783665157613813760
author Chung, Jung Wha
Choi, Hwa Young
Ki, Moran
Jang, Eun Sun
Jeong, Sook-Hyang
author_facet Chung, Jung Wha
Choi, Hwa Young
Ki, Moran
Jang, Eun Sun
Jeong, Sook-Hyang
author_sort Chung, Jung Wha
collection PubMed
description BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to investigate the detailed profiles of comorbidities and comedication among Korean CHC patients. METHODS: All adult patients (≥18 years old) with a primary diagnostic code of CHC in 2013 were selected from the National Health Insurance claims database. For each patient, all ICD-10 codes listed as primary or secondary diagnoses and all prescribed medications were collected. RESULTS: Among 47,104 CHC patients (median age, 57 years; male, 49.3%), 84.8% had at least one comorbidity for a mean number of 2.4, which increased with age. The most prevalent comorbidities were hypertension, esophagitis, dyslipidemia, diabetes mellitus, and peptic ulcer. Overall, 96.8% of the patients took at least one prescribed medication, with a mean of 8.1 medications/year, and the three most common drug types were analgesics, gastrointestinal agents, and antibacterials. Use of at least one drug with a DDI risk category of “contraindicated medication” or “required dose-reduction/additional monitoring” was observed in 97% of the overall patients. The proportion of prescribed medications that were contraindicated with DAAs varied from 2.0% to 38.9% depending on the hepatitis C virus regimen. CONCLUSIONS: The majority of CHC patients had comorbidities; almost all patients took multiple prescribed medications, the number of which increased with age, and significant DDI risk was present in 97% of this Korean patient cohort. Comorbidities and comedication profiles should be considered during DAA therapy.
format Online
Article
Text
id pubmed-7960981
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-79609812021-03-24 Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study Chung, Jung Wha Choi, Hwa Young Ki, Moran Jang, Eun Sun Jeong, Sook-Hyang Gut Liver Original Article BACKGROUND/AIMS: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to investigate the detailed profiles of comorbidities and comedication among Korean CHC patients. METHODS: All adult patients (≥18 years old) with a primary diagnostic code of CHC in 2013 were selected from the National Health Insurance claims database. For each patient, all ICD-10 codes listed as primary or secondary diagnoses and all prescribed medications were collected. RESULTS: Among 47,104 CHC patients (median age, 57 years; male, 49.3%), 84.8% had at least one comorbidity for a mean number of 2.4, which increased with age. The most prevalent comorbidities were hypertension, esophagitis, dyslipidemia, diabetes mellitus, and peptic ulcer. Overall, 96.8% of the patients took at least one prescribed medication, with a mean of 8.1 medications/year, and the three most common drug types were analgesics, gastrointestinal agents, and antibacterials. Use of at least one drug with a DDI risk category of “contraindicated medication” or “required dose-reduction/additional monitoring” was observed in 97% of the overall patients. The proportion of prescribed medications that were contraindicated with DAAs varied from 2.0% to 38.9% depending on the hepatitis C virus regimen. CONCLUSIONS: The majority of CHC patients had comorbidities; almost all patients took multiple prescribed medications, the number of which increased with age, and significant DDI risk was present in 97% of this Korean patient cohort. Comorbidities and comedication profiles should be considered during DAA therapy. Editorial Office of Gut and Liver 2021-03-15 2020-07-06 /pmc/articles/PMC7960981/ /pubmed/32616682 http://dx.doi.org/10.5009/gnl19387 Text en Copyright © Gut and Liver. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chung, Jung Wha
Choi, Hwa Young
Ki, Moran
Jang, Eun Sun
Jeong, Sook-Hyang
Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
title Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
title_full Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
title_fullStr Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
title_full_unstemmed Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
title_short Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
title_sort comorbidities and prescribed medications in korean patients with chronic hepatitis c: a nationwide, population-based study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960981/
https://www.ncbi.nlm.nih.gov/pubmed/32616682
http://dx.doi.org/10.5009/gnl19387
work_keys_str_mv AT chungjungwha comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy
AT choihwayoung comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy
AT kimoran comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy
AT jangeunsun comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy
AT jeongsookhyang comorbiditiesandprescribedmedicationsinkoreanpatientswithchronichepatitiscanationwidepopulationbasedstudy